1092 results about "Signal Pathways" patented technology

Described herein are methods of treating a disorder or disease in which aberrant Wnt signaling is implicated, with a variety of compounds, including Wnt inhibitor compounds. More particularly, it concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases due to mutations in Wnt signaling components.

The present inventors studied the effects of inhibiting the IL-6 signaling pathway on muscle cell growth. As a result, they discovered that, administering an IL-6 inhibitor can promote the adhesion, proliferation, and differentiation of satellite cells and therefore muscle regeneration.

The present invention provides a docking station (501) for a tablet computer (339) with or without an extended battery (301). This docking station (501) comprises a docking assembly for positioning with three degrees of freedom and having a data connector for mechanically supporting and interfacing with the tablet computer (339). A support member (505) couples the cradle (507) assembly to an expansion base (503). The base (503) includes a number of ports (54, 56, 60, 62) for interfacing with a variety of peripheral devices or power supplies. These varieties of ports mount to a printed circuit board contained within the expansion base (503). A flexible printed circuit (FPC) (64) combines the signal pathways for the variety of ports, allowing the signal pathways to travel from the printed circuit board (64) and to the data connector (519). The docking station (501) can support the tablet computer (339) in any orientation from landscape to portrait and can simultaneously charge both the tablets main battery (347) and the extended battery (301) while cradled in the docking station (501).

The invention provides methods and compositions for modulating the HGF / c-met signaling pathway, in particular by inhibiting a hyperstabilized c-met protein.

In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Nodal, anti-activin, and anti-GDF11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes.

A transcutaneous energy transfer system with subcutaneous non coupled coils is used to transmit power and signals to an implanted biological support device or sensor, such as a flow sensor for measuring relatively low flow rates, such as hydrocephalic shunt flow. The flow sensor is configured to convert a shear wave generated by a transducer to a longitudinal wave at the interface of a signal pathway and the flow, wherein the longitudinal wave travels parallel to the flow and exits a flow channel to convert to a shear wave which intersects a second transducer. The transcutaneous energy transfer employs a pair of inductive coupling coils, wherein the coils are disposed in zero coupling orientation which can include a perpendicular orientation of corresponding coil axes.

In certain aspects, the present invention provides compositions and methods for treating fatty liver disease by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies and anti-activin A or B antibodies. A variety of hepatic and metabolic disorders may be improved by treating fatty liver disease.

Methods and compositions are provided for the identification of stem cells and cancer stem cells. β-catenin is also identified as a target for the development of therapeutic moieties against hematopoietic tumors, i.e. leukemia and lymphoma cells, which may include screening assays directed at β-catenin, or members of the β-catenin signaling pathway. Cellular proliferation in hematopoietic cells can be altered by introducing stabilized β-catenin into a hematopoietic cell that is altered in its ability to undergo apoptosis but which is not fully transformed. The immortalized cells are useful in screening assays, and in the analysis of pathways by which hematopoietic cells undergo transformation.

A chimeric phosphorylation indicator (CPI) as provided herein can contain a donor molecule, a phosphorylatable domain, a phosphoaminoacid binding domain (PAABD), and an acceptor molecule. Where the phosphorylatable domain is phosphorylatable by protein kinase C (PKC), the CPI is a c-kinase activity reporter (CKAR). Donor and acceptor molecules may be, independently, fluorescent proteins such as non-oligomerizing fluorescent proteins. A CPI can contain a phosphorylatable polypeptide and a fluorescent protein; the phosphorylatable polypeptide may be contained within the sequence of the fluorescent protein, or the fluorescent protein may be contained within the sequence of the phosphorylatable polypeptide. The spatiotemporal properties of the PKC signal pathway may be tested with CKAR, calcium-sensing fluorophores and FRET-based translocation assays. Polynucleotides encoding such CPIs, and kits containing the indicators and / or the polynucleotides, are provided. A method of using the chimeric phosphorylation indicators to detect a kinase or phosphatase in a sample is provided.

This invention discloses methods and compositions for modulating immune responses, which involve particulate delivery of agents to immune cells, wherein the agents comprise an inhibitor of the NF-kappa B signaling pathway and an antigen that corresponds to a target antigen. The methods and compositions of the present invention are particularly useful in the treatment or prophylaxis of an undesirable immune response associated with the target antigen, including autoimmune diseases, allergies and transplantation associated diseases.

The embodiment of the invention provides a mobile terminal comprising a shell, a display screen, a camera and a receiver. The display screen provided with a first hole is arranged on the shell; the camera is arranged in the shell and is opposite to the first hole; the receiver is arranged between the display screen and the camera and communicates sound signals through the first hole; and an optical signal pathway is formed on the receiver and the camera collects external optical signals through the optical signal pathway and the first hole. According to the invention, because the camera is arranged under the receiver in the thickness direction of the mobile terminal, separate holes for the camera and the receiver are not needed to be formed in the display screen, the occupation of a hole in the display screen to the display area is reduced and the screen-to-body ratio of the display area of the display screen of the mobile terminal is increased.

The invention provides a method of determining whether tumor cells or tissue is responsive to treatment with an ErbB pathway-specific drug. In accordance with the invention, measurements are made on such cells or tissues to determine values for total ErbB receptors of one or more types, ErbB receptor dimers of one or more types and their phosphorylation states, and / or one or more ErbB signaling pathway effector proteins and their phosphorylation states. These quantities, or a response index based on them, are positively or negatively correlated with cell or tissue responsiveness to treatment with an ErbB pathway-specific drug. In one aspect, such correlations are determined from a model of the mechanism of action of a ErbB pathway-specific drug on an ErbB pathway. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more complexes formed in ErbB pathway activation. After binding, molecular tags are released and separated from the assay mixture for analysis.

A machine reading system is described herein that includes a framework in which grammar rules can be developed using a concise language that combines syntax and semantics. The resulting technology thus reduces the development time for new grammars in a new domain. An enormous amount of information appears in the form of natural language across millions of academic papers and other literature sources. For example, in the biological domain, there is a tremendous ongoing effort to extract individual chemical interactions from these texts, but these interactions are only isolated fragments of larger causal mechanisms such as protein signaling pathways. The proposed rule-based event extraction framework can model underlying syntactic representations of events in order to extract signaling pathway fragments. Though application to the biomedical domain is herein described, the framework is domain-independent and is expressive enough to capture most complex events annotated by domain experts.

A programmable logic device architecture including tristate structures. The programmable logic device architecture provides tristate structures which may be logically or programmably controlled, or both. Through these tristate structures, the logic elements may be coupled to the programmable interconnect, where they may be coupled with other logic elements of the programmable logic device. Using these tristate structures, the signal pathways of the architecture may be dynamically reconfigured.

The present invention relates to 1,2,4-oxadiazole compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD-1) signaling pathway and / or for treatment of disorders by inhibiting an immunosuppressive signal induced by PD-1, PD-L1 or PD-L2.

The instant application relates to methods and reagents for modulating the Hedgehog signaling pathway using RNA interference technology (RNAi). The application provides potential targets of the Hedgehog RNAi, methods to identify additional Hedgehog signaling pathway components, methods to inhibit Hedgehog signaling targets using siRNA, and their uses in the treatment of a number of disease conditions.

Provided is an anticancer agent which comprises an anti-PD-1 antibody or an anti-PD-L1 antibody as an active ingredient, functioning to reverse the unresponsiveness of iNKT cells in which anergy has been induced by administration with an iNKT cell ligand. The anti-PD-1 or anti-PD-L1 antibody blocks the PD-1 / PD-L1-mediated signaling pathway not only to prevent the iNKT cell ligand-induced iNKT cell anergy, but also to reverse the unresponsiveness of already anergic iNKT cells to produce cytokines. In addition, the anti-PD1 or anti-PD-L1 antibody ensures the potent anti-tumor activity of iNKT cells as demonstrated by a significant reduction in the number of metastatic nodules in B16F10 melanoma metastasis models in vivo. Collectively, the anticancer agent can be very useful in the treatment of cancer, particularly metastatic cancer.

Systems, among other embodiments, include topologies (data and / or control / address information) between an integrated circuit buffer device (that may be coupled to a master, such as a memory controller) and a plurality of integrated circuit memory devices. For example, data may be provided between the plurality of integrated circuit memory devices and the integrated circuit buffer device using separate segmented (or point-to-point link) signal paths in response to control / address information provided from the integrated circuit buffer device to the plurality of integrated circuit buffer devices using a single fly-by (or bus) signal path. An integrated circuit buffer device enables configurable effective memory organization of the plurality of integrated circuit memory devices. The memory organization represented by the integrated circuit buffer device to a memory controller may be different than the actual memory organization behind or coupled to the integrated circuit buffer device. The buffer device segments and merges the data transferred between the memory controller that expects a particular memory organization and actual memory organization.

The invention discloses a CRISPR / Cas9-gRNA targeting sequence pair, a plasmid and an HD model of HTT, and relates to the field of biotechnology. The targeting sequence pair of the invention comprisesan L sequence and an R sequence. The base sequence of the L sequence is shown as SEQ ID NO.1. The base sequence of the R sequence is shown as SEQ ID NO.2. The targeting plasmid of the invention comprises a first vector plasmid and the above-mentioned targeting sequence pair. The targeting sequence pair is constructed into the first vector plasmid. The HD cell model of the invention is obtained byco-transfecting cells with PolyQ Donor plasmids and the above-mentioned targeting plasmids. By using differentiated neuron cells as a carrier to construct the HD cell model, the invention provides a research platform for exploring the influences or changes of mHtt protein on the internal environment of differentiated nerve cells, and studying the changes of various signal pathways, metabolic pathways and intracellular homeostasis caused by mHtt protein in differentiated neuronal cells.

Matrix metalloproteinases are major mediators of tissue destruction in various chronic inflammatory disorders. The present invention demonstrates that over- expression of intracellular isoform of IL-1 receptor antagonist confers to recipient cells resistance to signaling pathways of proinflammatory cytokines (such as tumor necrosis factor alpha and IL-1 beta) that induce matrix metalloproteinase and subsequent tissue degradation. Hence, over-expression of intracellular IL-1 receptor antagonist may inhibit tissue destruction in various inflammatory disorders such as rheumatoid arthritis, other arthritides, degenerative intervertebral disc disease and chronic skin ulcers that occurs in diabetes mellitus and bed-ridden patients.

A method for improved ATE (automatic test equipment) timing calibration at a DUT (device under test). The method includes step of accessing a DUT component using an ATE component and performing physical calibration on a first portion of signal pathways coupling the ATE component to the DUT component. A simulation based calibration is performed on a second portion of signal pathways coupling the ATE component to the DUT component. The physical calibration results are combined with simulation based calibration results to calibrate timing propagation delay between the ATE component and the DUT component.

The invention discloses antibacterial and antitumor application of exosomes secreted by NK cells (aNK) activated by transmembrane IL-21 and multiple miRNAs contained in the exosomes, and provides a new method for bacterial infection and antitumor treatment. The method has the advantages that 1, the method is different from antibiotic treatment, and exosome antibiosis has lower side effects; 2, effects of antibacterial treatment can be enhanced through joint use; 3, the exosomes can be stored at low temperature, the miRNAs can be artificially synthesized, costs are low and large-scale production can be achieved; 4, the exosomes and the multiple miRNAs have inhibitory effects on a variety of bacteria, and have wider antibacterial spectra; 5, the miRNAs act on a variety of shared signal pathways of tumor cells, can inhibit a variety of tumors, and have a wide range of antitumor application.

Methods, compositions and kits are provided for assessing angiogenesis through sensitive, direct detection of activation of endothelial cells at molecular levels. In general, activation of endothelial cells is detected by measuring the levels of cellular components and their protein complexes participating in a specific angiogenesis signaling pathway in endothelial cells. The methods can be used for assessing status of diseases associated with undesirable angiogenesis, such as the likelihood of developing the disease, presence or absence of the disease, prognosis of the disease and the likelihood of response or resistance to a particular anti-angiogenic therapy. The methods can also be used to guide the design of effective therapeutic regimens targeting a specific angiogenic signaling pathway, as well as in conjunction with therapeutic intervention of diseases or conditions associated with undesirable angiogenesis.

The present invention relates to 1,3,4-oxadiazole and thiadiazole compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD-1) signaling pathway and / or for treatment of disorders by inhibiting an immunosuppressive signal induced by PD-1, PD-L1 or PD-L2.

The present invention provides a method of providing acute neuroprotection by inducing the erythropoietin (EPO) signaling pathway in neuronal cells close to or subsequent to the time of excitatory insult; and inducing an insulin-like growth factor (IGF) signaling pathway in the neuronal cells close to or subsequent to the time of excitatory insult, thereby producing a synergistic acute neuroprotective effect in the neuronal cells. The invention also provides a method of preventing or reducing the severity of a neurologic condition in a subject by administering to the subject EPO or an active fragment or analog thereof at a dose of at most 2000 U / kg; and administering to the subject an IGF or an active fragment or analog thereof, thereby providing neuroprotection and preventing or reducing the severity of the neurologic condition. Such a method can be used to prevent or reduce the severity of, for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, epilepsy, amyotrophic lateral sclerosis, multiple sclerosis, a movement disorder, HIV-associated dementia, HIV-associated neuropathy, neuropathic pain, migraine, glaucoma, drug addiction, drug withdrawal, drug dependency, depression or anxiety.